Rheumatoid Arthritis Drugs Global Market Report 2024

Description

“Rheumatoid Arthritis Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rheumatoid arthritis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rheumatoid arthritis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The rheumatoid arthritis drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids; Disease-Modifying Antirheumatic Drugs (DMARDs); Biologic Response Modifiers (BRMs); Other Drug Types
2) By Route Of Administration: Oral; Parenteral; Topical; Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Amgen Inc.; Novartis AG; Boehringer Ingelheim International GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Rheumatoid arthritis pharmaceuticals encompass medications designed for the management of an autoimmune disorder characterized by symptoms such as inflammation in the vicinity of joint tissues. These drugs aim to mitigate lasting damage to joints and other tissues while impeding the progression of rheumatoid arthritis.

The primary categories of rheumatoid arthritis pharmaceuticals consist of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers (BRMs), and other pharmaceutical classifications. NSAIDs, a subset of these drugs, are utilized for alleviating inflammation, fever, and other inflammatory conditions, offering advantages over steroids by minimizing adverse effects. Administration routes include oral, parenteral, topical, and alternative methods. The distribution channels for rheumatoid arthritis drugs encompass hospital pharmacies, retail pharmacies, and online pharmacies..

The rheumatoid arthritis drugs market research report is one of a series of new reports from The Business Research Company that provides rheumatoid arthritis drugs market statistics, including rheumatoid arthritis drugs industry global market size, regional shares, competitors with a rheumatoid arthritis drugs market share, detailed rheumatoid arthritis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatoid arthritis drugs industry. This rheumatoid arthritis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rheumatoid arthritis drugs market size has grown marginally in recent years. It will grow from $60.82 billion in 2023 to $61.06 billion in 2024 at a compound annual growth rate (CAGR) of 0.4%. The expansion observed in the historical period can be ascribed to several factors, including the rising prevalence of diseases, advancements in healthcare infrastructure, increased awareness and educational efforts, governmental initiatives and support, as well as strategic collaborations.

The rheumatoid arthritis drugs market size is expected to see marginal growth in the next few years. It will grow to $64.86 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The anticipated expansion during the forecast period is primarily driven by the prevailing trends in personalized medicine, the burgeoning growth of emerging markets, ongoing advancements in pipeline development, a concerted emphasis on combination therapies, and a notable rise in healthcare expenditure. Key trends expected to shape the forecast period encompass the dominant role of biological therapies, the impact of biosimilars, advancements in personalized medicine, the burgeoning growth of oral therapies, and a heightened focus on early diagnosis and intervention.

The anticipated surge in arthritis cases is poised to drive the expansion of the rheumatoid arthritis drugs market in the coming years. Rheumatoid arthritis, characterized by autoimmune and inflammatory responses causing damage to healthy cells and resulting in painful swelling, has effective treatment options in the form of drugs and self-management techniques. These interventions aim to reduce pain, improve joint flexibility, and impede the progression of the disease. Notably, recent data from the Centers for Disease Control and Prevention (CDC) highlights a significant rise in arthritis cases, with 54.4 million adults diagnosed in the United States in 2021, projected to reach 78 million by 2040. Consequently, the increasing prevalence of arthritis is expected to be a key driver for the rheumatoid arthritis drug market.

The expanding elderly population is anticipated to contribute significantly to the growth of the rheumatoid arthritis drugs market. The term "elderly population" denotes individuals aged 65 and above, relative to the working-age population (18 to 64 years old). Managing rheumatoid arthritis in the elderly presents challenges and opportunities, with newer drugs such as JAK inhibitors and targeted synthetic DMARDs offering alternative options with potentially safer profiles for this demographic. As reported by ReliefWeb in July 2022, the global population of individuals aged 65 or older is projected to increase from 10% in 2022 to 16% in 2050, reaching 94 million and comprising 23% of the total population. Hence, the growth of the elderly population is a key factor propelling the rheumatoid arthritis drugs market.

The rheumatoid arthritis drug market is witnessing a notable trend in product innovations, with companies strategically embracing new product launches to maintain and enhance their market positions. One such example is the introduction of Olokizumab by R-Pharm, a Russian high-tech pharmaceutical company, in August 2022. Olokizumab is a humanized monoclonal antibody targeting the cytokine interleukin-6, a key player in the progression of joint destruction in rheumatoid arthritis. This innovative product, similar to TNF (tumor necrosis factor), mitigates inflammatory responses, thereby reducing disease activity in many rheumatoid arthritis patients.

Major players in the rheumatoid arthritis drug market are actively engaged in pioneering solutions, such as subcutaneous injection, to gain a competitive advantage. Subcutaneous injections, also known as sub-q or SQ injections, involve delivering medication just beneath the skin. For instance, Eisai Co Ltd. and Nippon Medac Co Ltd. collaborated to launch the Metoject Subcutaneous Injection Syringe in November 2022. This product represents the first self-administrable prefilled syringe formulation of methotrexate (MTX) for rheumatoid arthritis approved in Japan. The Metoject Subcutaneous Injection Syringe is user-friendly, featuring a thin, 27-gauge needle for a more comfortable injection experience, a clear injection window, and a straightforward plunger mechanism to facilitate easy self-administration.

In October 2023, Amgen Plc, a prominent US-based biotechnology company, completed the acquisition of Horizon Therapeutic Plc for $27.8 billion. This strategic move enhances Amgen's inflammation portfolio by incorporating first-in-class, early-in-lifecycle medicines designed to treat rare inflammatory diseases. Horizon Therapeutic Plc, an Ireland-based biopharmaceutical company, specializes in providing treatments for focal segmental glomerulosclerosis, kidney transplant rejection, and rheumatoid arthritis drugs. This acquisition positions Amgen to strengthen its position in the market through a diversified and expanded product offering.

Major companies operating in the rheumatoid arthritis drugs market report are Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A. Belgium., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Chr. Hansen Holding A/S, Ipsen S.A, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

North America was the largest region in the rheumatoid arthritis drugs market in 2023. North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rheumatoid arthritis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The rheumatoid arthritis drugs market consists of sales of products such as abatacept, aceclofenac and adalimumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12052

1. Executive Summary

2. Rheumatoid Arthritis Drugs Market Characteristics

3. Rheumatoid Arthritis Drugs Market Trends And Strategies

4. Rheumatoid Arthritis Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Rheumatoid Arthritis Drugs Market Size and Growth

5.1. Global Rheumatoid Arthritis Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Rheumatoid Arthritis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Rheumatoid Arthritis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Rheumatoid Arthritis Drugs Market Segmentation

6.1. Global Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Corticosteroids
Disease-Modifying Antirheumatic Drugs (DMARDs)
Biologic Response Modifiers (BRMs)
Other Drug Types
6.2. Global Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Topical
Other Route Of Administrations
6.3. Global Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

7. Rheumatoid Arthritis Drugs Market Regional And Country Analysis

7.1. Global Rheumatoid Arthritis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Rheumatoid Arthritis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Rheumatoid Arthritis Drugs Market

8.1. Asia-Pacific Rheumatoid Arthritis Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Rheumatoid Arthritis Drugs Market

9.1. China Rheumatoid Arthritis Drugs Market Overview
9.2. China Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Rheumatoid Arthritis Drugs Market

10.1. India Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Rheumatoid Arthritis Drugs Market

11.1. Japan Rheumatoid Arthritis Drugs Market Overview
11.2. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Rheumatoid Arthritis Drugs Market

12.1. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Rheumatoid Arthritis Drugs Market

13.1. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Rheumatoid Arthritis Drugs Market

14.1. South Korea Rheumatoid Arthritis Drugs Market Overview
14.2. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Rheumatoid Arthritis Drugs Market

15.1. Western Europe Rheumatoid Arthritis Drugs Market Overview
15.2. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Rheumatoid Arthritis Drugs Market

16.1. UK Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Rheumatoid Arthritis Drugs Market

17.1. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Rheumatoid Arthritis Drugs Market

18.1. France Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Rheumatoid Arthritis Drugs Market

19.1. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Rheumatoid Arthritis Drugs Market

20.1. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Rheumatoid Arthritis Drugs Market

21.1. Eastern Europe Rheumatoid Arthritis Drugs Market Overview
21.2. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Rheumatoid Arthritis Drugs Market

22.1. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Rheumatoid Arthritis Drugs Market

23.1. North America Rheumatoid Arthritis Drugs Market Overview
23.2. North America Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Rheumatoid Arthritis Drugs Market

24.1. USA Rheumatoid Arthritis Drugs Market Overview
24.2. USA Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Rheumatoid Arthritis Drugs Market

25.1. Canada Rheumatoid Arthritis Drugs Market Overview
25.2. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Rheumatoid Arthritis Drugs Market

26.1. South America Rheumatoid Arthritis Drugs Market Overview
26.2. South America Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Rheumatoid Arthritis Drugs Market

27.1. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Rheumatoid Arthritis Drugs Market

28.1. Middle East Rheumatoid Arthritis Drugs Market Overview
28.2. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Rheumatoid Arthritis Drugs Market

29.1. Africa Rheumatoid Arthritis Drugs Market Overview
29.2. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Rheumatoid Arthritis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Rheumatoid Arthritis Drugs Market Competitive Landscape And Company Profiles

30.1. Rheumatoid Arthritis Drugs Market Competitive Landscape
30.2. Rheumatoid Arthritis Drugs Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. AbbVie Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Amgen Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Boehringer Ingelheim International GmbH
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Rheumatoid Arthritis Drugs Market Competitive Benchmarking

32. Global Rheumatoid Arthritis Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Rheumatoid Arthritis Drugs Market

34. Rheumatoid Arthritis Drugs Market Future Outlook and Potential Analysis

34.1 Rheumatoid Arthritis Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Rheumatoid Arthritis Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Rheumatoid Arthritis Drugs Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer